Table 3 Baseline characteristics of prostate cancer group.
Prostate cancer group | ||||||
|---|---|---|---|---|---|---|
N (132) | Age (years) Mean (range) | PSA serum level (ng/mL) Mean (range) | Clinical stage | Pathological Gleason Score | Pathological stage | |
Low risk PCa | 23 | 61 (52–74) | 7.26 (3–17.5) | T1c | 3 + 3 | pT2a–pT2c |
Intermediate risk PCa | 47 | 65 (50–78) | 7.32 (1.5–29) | T1c | 3 + 4 | pT2a–pT3 |
High risk PCa | 48 | 63 (50–77) | 10.8 (0.60–62) | T1c–T3 | > 3 + 4 | pT2a–pT3b |
PCa at prostate biopsy | 7 | 59 (46–75) | 5.4 (3.2–9.0) | T1c | 3 + 3; 3 + 4; 4 + 3 | |
PCa biochemical relapse | 3 | 69 (61–79) | 1 (0.6–2.1) | |||
Metastatic PCa | 4 | 71 (66–84) | 12 (10–78) | |||
